おすすめの製品
![Methyl 3-[[(2RS)-2-(dipropylamino)propanoyl]-amino]-4-methylthiophene-2-carboxylate hydrochloride certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland](/deepweb/assets/sigmaaldrich/product/structures/386/957/d524e439-2ea8-42c4-a86f-ffa3878e9091/640/d524e439-2ea8-42c4-a86f-ffa3878e9091.png)
グレード
pharmaceutical primary standard
APIファミリー
bromperidol
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
BrC(C=C1)=CC=C1C(CC2)(O)CCN2CCCC(C3=CC=C(F)C=C3)=O
InChI
1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
InChI Key
RKLNONIVDFXQRX-UHFFFAOYSA-N
遺伝子情報
human ... DRD2(1813)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
アプリケーション
Bromperidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生物化学的／生理学的作用
Butyrophenone antipsychotic; D2 dopamine and 5-HT2A serotonin antagonist.
包装
この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。
その他情報
Sales restrictions may apply.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
T Suzuki et al.
Journal of clinical pharmacy and therapeutics, 32(5), 525-527 (2007-09-19)
To report the usefulness of antipsychotic dose-reduction for avoiding paralytic ileus in a patient with chronic schizophrenia and comorbid dementia. A 65-year-old in-patient developed severe paralytic ileus warranting a transfer to the general hospital. Constipation was very troublesome and he
A Suzuki et al.
European archives of psychiatry and clinical neuroscience, 251(2), 57-59 (2001-06-16)
The relationship between TaqI A dopamine D2 receptor (DRD2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6-18 mg/day for 3 weeks. Clinical symptoms were
C Ohye et al.
Stereotactic and functional neurosurgery, 77(1-4), 33-39 (2002-10-16)
Recent advances on understanding the pallidothalamic relation lead us to perform Vim-Vo thalamotomy (combined thalamic lesion in ventralis intermedius nucleus and ventralis oralis nucleus) for cases with dyskinesia. In our recent series of thalamotomies, there are 12 cases of dyskinesia
Norio Yasui-Furukori et al.
Therapeutic drug monitoring, 26(3), 336-341 (2004-05-29)
The authors have developed and verified the precision and accuracy of new automated cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol, and cross-validations have been performed with conventional semiautomated EIA kits (MARKIT-M) and high-performance liquid chromatographic (HPLC) methods. The
P Benfield et al.
Drugs, 35(6), 670-684 (1988-06-01)
Bromperidol is a close structural analogue of haloperidol. Both agents possess similar pharmacodynamic properties which are consistent with central antidopaminergic activity. The available clinical data from non-comparative and comparative trials have shown that bromperidol possesses antipsychotic activity. Its overall efficacy
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）